
ICE as sole imaging guidance for TTVR- initial case series highlights feasibility and efficiency advantages sciencedirect.com/science/ar… @DrConorLane

Interventional cardiologist @MayoClinic | Valvular Heart Disease | Structural Interventions & Hemodynamics | Tweets are my own

ICE as sole imaging guidance for TTVR- initial case series highlights feasibility and efficiency advantages sciencedirect.com/science/ar… @DrConorLane

Edge to edge repair in SAM-mediated LVOT obstruction case series by @markjzorman et al. authors.elsevier.com/sd/arti… @MyJSCAI

Transcatheter replacement achieved more complete TR reduction and greater forward stroke volume, with acute increase in RV systolic pressure @JabbarMMS

TEER was associated with greater acute RA pressure reduction and more favorable RV remodeling @JabbarMMS

What are the differential hemodynamic effects of tricuspid TEER vs replacement? ahajournals.org/doi/epub/10.… @JabbarMMS

@djc795 @benhibbertMDPhD @GreggWStone when HFH is used as a criteria to allow crossover early after randomization how does this impact its validity as an endpoint?

The HFH curves diverge early which may be explained by trial design- crossover to device arm was allowed after 30 days if a heart failure hospitalization where IV diuretic was administered occurred. This simple difference in trial design may be a key factor.

TRIC-HF presented today at ESC is the first RCT of transcatheter tricuspid repair to show a large reduction of HF hospitalization
Presented at #ESCCongress: In patients with severe tricuspid regurgitation and heart failure, transcatheter tricuspid-valve repair plus medical therapy was superior to medical therapy alone in reducing hospitalizations for heart failure and deaths. Full TRIC-I-HF trial results: nej.md/4ilZJGr @escardio


When should you recommend tricuspid intervention? Malcolm Bell, MD interviews @EleidMack on strengths/weaknesses of transcatheter repair vs replacement, current evidence, and key knowledge gaps shaping #CathLab decisions for #vhdTR. Listen here: cardiovascularcmemayoclinic.…

Younger patients with aortic stenosis require lifetime planning. Malcolm Bell, MD interviews @EleidMack on indications, advantages, and tradeoffs of #TAVR vs #SAVR and shared decision-making in #cvVHD. Get more here: cardiovascularcmemayoclinic.…

Secondary TR in pulmonary #hypertension is assoc w/ ⬆️symptoms, ⬆️congestion, & ⬆️mortality, beyond assoc RV dysfunction. Secondary TR could serve as a potential future therapeutic target. jacc.org/doi/10.1016/j.jcmg.… #JACCIMG #cvVHD #vhdTR @sarano_maurice @EleidMack @MayoClinicCV

A thought provoking study by @AbdullahAlabcha from the @MayoClinicCV dataset on patients with moderate MR. Natural History and Outcomes of Patients With Moderate and Moderate-Severe Mitral Regurgitation - tinyurl.com/49xpdvae

Congrats to our graduating SHD interventional fellows- proud of you! The future is bright @MayoClinicCV @MayoCVFellows

In MVIV, valve expansion matters! Check out our @CircIntv study by @markjzorman showing THV underexpansion a/w increased all-cause mortality, heart failure readmission, and valve reintervention. ahajournals.org/doi/10.1161/…

Dive deep with us into the intricacies of #CathLab. Case-based learning grants insights and practical strategies for managing complex cases. Register now: mayocl.in/48RhfNw #ACCIV @EleidMack @aelsab